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     SUMMARY
Objectives: To determine the extend of comorbidity present in HIV positive and negative 
patients with respiratory tract infections.
Methods: Descriptive cross sectional study. Between October 2002 and December 2003 88 
bronchoscopies were analysed at Mulago teaching hospital.
Results: 70.5% of the patients were HIV positive with a mean age of 35.1 years. In the HIV positive 
group, PKS was the most frequent diagnosis made (38.7%), followed by PCP (37.1%) and PTB 
(14.5%). In the HIV negative group, lung malignancy was the commonest diagnosis found. Ten 
of the HIV positive patients (16.1%) had two or more pulmonary diseases: two patients had 
both PCP and PTB, three patients had PKS and PTB, four patients had PKS and PCP, and one 
patient had PCP, PKS and PTB. When we analysed according to diseases, 30.4% (7/23) of PCP 
patients had other opportunistic diseases, PKS patients, 30.0% (8/24) and PTB patients, 66.7 
% (6/9). 
Conclusion: The presence of multiple infectious agents may explain why some HIV positive 
patients with respiratory disease show only temporary clinical improvement. This suggests 
that one diagnosis may not be enough for HIV patients.
    
    [Afr J Health Sci. 2010; 17:31-35]
Introduction
Even though the frequency of opportunistic respiratory 
infections is decreasing since the introduction of 
antiretroviral therapy (ARV), respiratory diseases 
are still a main cause of mortality and morbidity in 
HIV infected patients.  ,  In Uganda, where less than 
50% of HIV patients who need ARV have access to it, 
many patients are admitted to hospitals with advanced 
immunosuppression. We have seen some patients 
on treatment for Pneumocystis jiroveci pneumonia 
(PCP) who deteriorate after an initial improvement; 
some of these patients were later proven to have other 
pulmonary diseases, such as pulmonary tuberculosis 
(PTB) or pulmonary Kaposi’s sarcoma (PKS). Though 
the presence of dual or more pathogens in HIV patients 
has been reported in the early HIV epidemic, ,  we 
hardly find literature that demonstrates the severity or 
prevalence of respiratory co-morbidity in HIV positive 
patients.
Materials and methods
A descriptive cross-sectional study was undertaken.
Patient selection
Between October 2002 and December 2003, 124 
bronchoscopies were performed in the bronchoscopy 
unit of Mulago teaching hospital in Kampala, Uganda. 
The patients were referred from inpatients wards and 
the out patient department of Mulago hospital, and 
other hospitals. Bronchoscopy was performed on those 
patients if three sputum smears of Acid Fast Bacilli 
(AFB) were negative or they could not produce sputum 
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effectively. All of them agreed to get bronchoscopy 
examinations.
We selected the patients who had agreed to do HIV 
serology test. We also analysed the indications for 
bronchoscopy for the patients.
Bronchoscopy and laboratory examinations
Bronchoscopy with bronchoalveolar lavage (BAL) 
was done on every patient and a Ziehl Neelsen stain 
for AFBs was carried out on all BAL fluid samples. 
Immunofluorescent staining using monoclonal 
antibodies against Pneumocystis jiroveci glycoprotein 
was performed on the BAL samples only when the 
patient was HIV seropositive. Where malignancy was 
suspected, the washing fluid was taken for cytological 




The number of patients was 88 (46 male, 42 female), 
of these sixty two patients (70.5 %) out of 88 were HIV 
seropositive. The mean age of the 88 patients was 40.2 
years (range 18 to 79). The mean age of HIV positive 
group was 35.1 years, and that of HIV negative 52.4 
years. 10 patients had a history of taking ARVs.
Table 1. Indications of Bronchoscopy 
 
Indications  HIV (+) group HIV (-) group
  Lung mass/nodule         4          12
  Hemoptysis          2           4
  Atelectasis          0           4
  PTB/Pneumonia          5           4
  HIV associated
  infection/PKS         49          0
  Others           2          2
  Total No.         62          26
In the HIV seropositive group, 79.0% of the 
subjects were referred for bronchoscopy because 
attending doctors had thought they had HIV associated 
opportunistic diseases, such as PCP or PKS. While the 
most common indication of bronchoscopy for HIV 
seronegative group was a lung mass on chest x-ray 
(46.2%). 
In the HIV positive group, PKS was the most 
frequent diagnosis made in 38.7%, followed by PCP 
(37.1%) and PTB (14.5%). In the HIV negative group, 
lung malignancy was the commonest diagnosis found. 
Among these a histological diagnosis of squamous 
cell carcinoma was found more often than 
adenocarcinoma.
Table 2. The diagnoses of pulmonary diseases confirmed by 
bronchoscopy.
Diagnosis  HIV positive (62)      HIVnegative (26)
PKS*        24 (38.7%)       0
PCP        23 (37.1%)       0
PTB        9 (14.5%)       2 (8.0%)
Suppurative lung disease**       4 (6.5%)       3 (11.5%)
Squamous cell carcinoma      0        6 (23.0%)
Adenocarcinoma       0        2 (8.0%)
Metastatic carcinoma      0        2 (8.0%)
No diagnosis       10 (16.1%)      11 (42.3%)
* The diagnosis was made when Kaposi’s sarcoma (KS)-plaques were 
found on bronchoscopy and KS was confirmed by biopsy specimen 
from other sites such as skin or oral mucosa.
** The diagnosis was made when pus-like secretion was found in the 
airway, but AFBs were not found while many bacteria were found on 
the stain.
In the HIV seropositive group 10 (16.1%) patients 
had two or more pulmonary diseases: two (3.2%) 
patients had both PCP and PTB, three (4.8%) patients 
had PKS and PTB, four (6.4%) patients had PKS and 
PCP, and one (1.6%) patient had PCP, PKS and PTB. 
In contrast, the HIV seronegative group had no co-
morbidities. 
Table 3. Co-morbidity of respiratory diseases in patients 
presenting to the bronchoscopy unit 
Co-morbidity HIV positive group          HIV negative group
       10 (16.1%)   0 (0%)
PCP + PTB  2  0
PKS + PTB  3  0
PKS + PCP  4  0
PCP + PKS + PTB  1  0
When we analysed according to diseases, 30.4% 
(7/23) of PCP patients had other opportunistic diseases, 
PKS patients, 30.0% (8/24) and PTB patients, 66.7 % 
(6/9). (Table 4)
Table 4. The prevalence of co-morbidity in each disease
Diagnosis Patients number Number of Co-morbidity
PKS    24  8 (33.3%)
PCP   23  7 (30.4%)
PTB   9  6 (66.7%)
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Discussion
HIV sero-status of patients
In this study, 70.5% (62/88) of patients who were 
transferred for bronchoscopy were HIV seropositive. 
Even though this percentage does not directly reflect 
HIV seropositivity among patients with respiratory 
diseases in Uganda, this feature indirectly shows that 
HIV infection still is a major cause of undiagnosed 
respiratory illness in clinical practice.
The mean age of HIV positive group was younger 
than that of HIV negative group. This correlates with 
national data that the peak of HIV seropositivity is 
between 20-40 years.  
The result of bronchoscopy
In the HIV positive group, PKS was the commonest 
diagnosis (38.7%), followed by PCP (37.1%) and PTB 
(14.5%). According to Worodria et al under a similar 
setting the study findings were different.   At that 
time, the most common diagnosis was PCP (38.6%), 
followed by PTB (24%), and PKS (11%).
In the current study the prevalence of PTB and PCP 
was similar to that study, but the prevalence of PKS 
was much higher. The reason for the high prevalence of 
PKS is not clear, but this might be due to the increased 
awareness of medical doctors that PKS is common 
in KS patients. Therefore, more patients with KS are 
referred for bronchoscopy to confirm the diagnosis of 
PKS than before.
PKS
The diagnosis of PKS was made at bronchoscopy 
when typical violaceous lesions of KS were identified 
in the endobronchial tree in patients who had KS lesions 
that was confirmed by biopsy of other sites of the body 
such as the skin or oral mucosa. In our study, PKS was 
found in 38.7% of the subjects. The incidence of PKS 
is difficult to assess because, even with bronchoscopy, 
the diagnosis is not established in every case. Mitchell 
and Miller reported that only 45% of cases have 
endobronchial lesions located at segmental orifices in 
the main trachea or bronchi where bronchoscope can 
reach.  However, bronchoscopy is still the most useful 
tool in making the diagnosis of PKS. According to 
postmortem studies, PKS has been found in 47% of 
patients with cutaneous KS  and 59% of patients dying 
with AIDS had KS, that was unsuspected premortem in 
any patient.  Therefore, the incidence of PKS in AIDS 
patients may be approximately 30%. PKS should be 
considered in the differential diagnosis of all patients with 
HIV infection presenting with respiratory symptoms. 
PCP
The prevalence of PCP in this study was 37.1%. It 
was similar to Worodria et al 5 that showed 38.6%. In 
earlier studies, the prevalence of PCP was quite lower 
than these with range of 5-11%. Those studies most 
probably showed a lower prevalence of PCP than recent 
studies because they used other staining methods other 
than the immunoflorescent stain using monoclonal 
antibodies that is regarded as the “gold standard”.
PTB
In keeping with others studies in Africa, our 
study shows a high prevalence of TB among sputum 
AFB smear negative patients. Batungwanayo et al 
found 23% of the patients with pulmonary disease of 
unknown etiology had TB in Rwanda12. In Worodria 
et al study, the prevalence of TB was 24% and the ZN 
stain for AFB showed positive in 55% of them5. By 
culture it was possible to identify 45% of patients that 
were initially AFB smear negative on BAL fluid. We 
did ZN stain on the BAL fluid but TB cultures were 
not done. This could explain why the prevalence of TB 
was not as high as in other studies. 
One challenge in making a diagnosis of TB is the 
reliability of ZN stain. If AFB are identified from 
sputum or from BAL fluid samples, can we confidently 
make a diagnosis of PTB? The prevalence of atypical 
mycobacteria in developed countries is increasing. 
However, in developing countries where TB is very 
prevalent, the prevalence of atypical mycobacterial 
infection is negligible . Worodria et al anaylsed BAL 
fluid from HIV seropositve group, but found no 
atypical mycobacterium from the culture.5 Therefore, 
in programmatic situations recommendations that 
doctors should start antituberculous treatment based 
on positive sputum AFB is reasonable. 
Pulmonary co-morbidity
The indications for bronchoscopy in table 1 in 
HIV seropositive and negative groups are presented 
in table 1. Because the indications for bronchoscopy 
were different in the two groups, we cannot compare 
their results. However, the point is very clear that there 
are pulmonary co-mobidities in the HIV seropositive 
group while no co-morbidity was observed in HIV 
seronegative group. 
The present study shows that 10 patients (16.1%) 
had two or more pulmonary diseases: two patients had 
both PCP and PTB, three patients had PKS and PTB, 
four patients had PKS and PCP, and one patient had 
PCP, PKS and PTB. 
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The presence of pulmonary comorbidity has 
been reported in Sub-Sahara Africa. Batungwanayo 
et al 12 reported pulmonary co-morbidity in HIV 
positive patients. In their study among 14 pulmonary 
cryptococcosis patients, 2 patients had PTB and one 
had PKS in addition. Worodria et al reported 5 patients 
had PCP and PTB, 3 patients PCP and PKS, and one 
patient PKS and PTB among 83 
admitted patients.5 Yoo et al found that 5 patients 
had PTB, and one patient PCP among 20 PKS patients 
in Uganda.  However, the percentage of co-morbidity 
in those studies is unclear.
In the present study (Table 4), among patients 
diagnosed with PCP, 30.4% (7/23) of them had other 
opportunistic diseases, in PKS patients, 30.0% (8/24) 
and among PTB patients, 66.7 % (6/9). This implies 
that pulmonary co-morbidity in HIV patients is not 
rare. 
At the time of this study most HIV positive 
patients in this study did not have access to ARVs, and 
CD4 count tests were not routinely available. It was 
not possible to stratify the diseases pattern according 
to CD4 counts. However currently there are country-
wide efforts to scale up provision of ARVs to eligible 
HIV positive patients. Furthermore the cost of CD4 
count is getting cheaper, so future studies may be able 
to analyse the different disease patterns according to 
different CD4 levels. 
Due to lack of laboratory diagnostic facilities, 
we could not investigate the presence or absence of 
viral or fungal infections. It is very likely that more 
pulmonary co-morbidities would have been found 




Pulmonary comorbidity is common in HIV positive 
patients. The presence of multiple infectious agents 
may explain why some HIV positive patients with 
respiratory disease show only temporary clinical 
improvement. This suggests that one diagnosis may 
not be enough for HIV patients.
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